[
  {
    "ts": null,
    "headline": "Bristol Myers Dives After Promising Schizophrenia Drug Flops In Phase 3 Test",
    "summary": "Shares of Bristol Myers Squibb tumbled Wednesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 study.",
    "url": "https://finnhub.io/api/news?id=56ef8ad7e252e97c43b747c6bb9ea06020864d9698a46a6c24c65af8ed40509b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745357136,
      "headline": "Bristol Myers Dives After Promising Schizophrenia Drug Flops In Phase 3 Test",
      "id": 134046629,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Shares of Bristol Myers Squibb tumbled Wednesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 study.",
      "url": "https://finnhub.io/api/news?id=56ef8ad7e252e97c43b747c6bb9ea06020864d9698a46a6c24c65af8ed40509b"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test",
    "summary": "Shares of Bristol Myers Squibb tumbled late Tuesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 study.",
    "url": "https://finnhub.io/api/news?id=82f9176ed0747ded4db7c78fc1096de2745d2deffd47ce175e080f0a431ea056",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745357136,
      "headline": "Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test",
      "id": 134039081,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Shares of Bristol Myers Squibb tumbled late Tuesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 study.",
      "url": "https://finnhub.io/api/news?id=82f9176ed0747ded4db7c78fc1096de2745d2deffd47ce175e080f0a431ea056"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia",
    "summary": "PRINCETON, N.J., April 22, 2025--BMS Announces Topline Results from Phase 3 ARISE Trial",
    "url": "https://finnhub.io/api/news?id=78c3be7e9e06a65c7a0a5707eb8c1340c73ead873f9cd6f85367df84fb2817b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745352900,
      "headline": "Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia",
      "id": 134039082,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., April 22, 2025--BMS Announces Topline Results from Phase 3 ARISE Trial",
      "url": "https://finnhub.io/api/news?id=78c3be7e9e06a65c7a0a5707eb8c1340c73ead873f9cd6f85367df84fb2817b7"
    }
  },
  {
    "ts": null,
    "headline": "Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025",
    "summary": "Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025",
    "url": "https://finnhub.io/api/news?id=7e347350066bf0041b6f9b9af398bb92318a4d3596d3fe0684d2bbc7e4d2d1fa",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745345110,
      "headline": "Neurocrine Biosciences: Valbenazine As Adjunctive Therapy Could Stage Comeback In 2025",
      "id": 134037064,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=7e347350066bf0041b6f9b9af398bb92318a4d3596d3fe0684d2bbc7e4d2d1fa"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb's Schizophrenia Treatment Falls Flat",
    "summary": "By Kelly Cloonan Bristol Myers Squibb's Cobenfy as an adjunctive treatment did not reach the threshold for a statistically significant difference compared to a placebo with an atypical...",
    "url": "https://finnhub.io/api/news?id=44fd6a90221d7df46dc149d0bcb3fab8008ac9dad71c80c3a06b5dbca430fdc8",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745342178,
      "headline": "Bristol Myers Squibb's Schizophrenia Treatment Falls Flat",
      "id": 134036629,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "By Kelly Cloonan Bristol Myers Squibb's Cobenfy as an adjunctive treatment did not reach the threshold for a statistically significant difference compared to a placebo with an atypical...",
      "url": "https://finnhub.io/api/news?id=44fd6a90221d7df46dc149d0bcb3fab8008ac9dad71c80c3a06b5dbca430fdc8"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock rises Tuesday, still underperforms market",
    "summary": "Bristol Myers Squibb Co. stock rises Tuesday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=696afc186b02eb52923e38a3e5bd868f6e5a2617910300cc109598896f0bc048",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745339880,
      "headline": "Bristol Myers Squibb Co. stock rises Tuesday, still underperforms market",
      "id": 134074865,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock rises Tuesday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=696afc186b02eb52923e38a3e5bd868f6e5a2617910300cc109598896f0bc048"
    }
  },
  {
    "ts": null,
    "headline": "NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release",
    "summary": "NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=75d05d5b9338929b4299c5182f14c9c169376c85971730dbb5b83224329ed4f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745330456,
      "headline": "NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release",
      "id": 134039083,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=75d05d5b9338929b4299c5182f14c9c169376c85971730dbb5b83224329ed4f4"
    }
  },
  {
    "ts": null,
    "headline": "Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=e691f7fd45ad9ed3cb4226301754e856ba5e1dc168384e43ed0210b285a434ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745329205,
      "headline": "Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term",
      "id": 134039084,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=e691f7fd45ad9ed3cb4226301754e856ba5e1dc168384e43ed0210b285a434ae"
    }
  },
  {
    "ts": null,
    "headline": "Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?",
    "summary": "Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.",
    "url": "https://finnhub.io/api/news?id=fc7284558b260b2aa35915f10fea13d539f12765babd08abe505f1f79771400b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745327160,
      "headline": "Will These 5 Large Drug Maker Stocks Surpass Q1 Earnings Forecast?",
      "id": 134038512,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Let's look at five big pharma companies, GILD, BMY, MRK, ABBV and SNY slated to release their first-quarter 2025 results this week.",
      "url": "https://finnhub.io/api/news?id=fc7284558b260b2aa35915f10fea13d539f12765babd08abe505f1f79771400b"
    }
  },
  {
    "ts": null,
    "headline": "Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)",
    "summary": "Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 billion acquisition of MyoKardia for its obstructive hypertrophic myopathy (HCM) drug, Camzyos, in 2020, the pharmaceutical giant has had difficulty achieving a return on investment. Bristol once believed Camzyos, FDA-approved for obstructive HCM (oHCM), could generate $4 billion in peak annual sales, but this has taken a hit on many fronts. Last week, Bristol revealed th",
    "url": "https://finnhub.io/api/news?id=a7e34496c5878cb4707388a608718e0dafb2d03d89b7ba953751cbde5e26d3dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745324791,
      "headline": "Patent Cliff Looms Large for Bristol-Myers Squibb Stock (BMY)",
      "id": 134039086,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 billion acquisition of MyoKardia for its obstructive hypertrophic myopathy (HCM) drug, Camzyos, in 2020, the pharmaceutical giant has had difficulty achieving a return on investment. Bristol once believed Camzyos, FDA-approved for obstructive HCM (oHCM), could generate $4 billion in peak annual sales, but this has taken a hit on many fronts. Last week, Bristol revealed th",
      "url": "https://finnhub.io/api/news?id=a7e34496c5878cb4707388a608718e0dafb2d03d89b7ba953751cbde5e26d3dd"
    }
  },
  {
    "ts": null,
    "headline": "Iovance Biotherapeutics: Only For The Brave",
    "summary": "Iovance Biotherapeutics: Only For The Brave",
    "url": "https://finnhub.io/api/news?id=30efbab55526e45b4954739567e81037252b203a424c9b7b816339547b7674a9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745305747,
      "headline": "Iovance Biotherapeutics: Only For The Brave",
      "id": 134031617,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=30efbab55526e45b4954739567e81037252b203a424c9b7b816339547b7674a9"
    }
  },
  {
    "ts": null,
    "headline": "Bristol-Myers Squibb: Extraordinary Dividend And FCF Yields Ready For Recession",
    "summary": "Bristol-Myers Squibb: Extraordinary Dividend And FCF Yields Ready For Recession",
    "url": "https://finnhub.io/api/news?id=2383ceb3bd63593652dd9ff902c086f52601c8a595b8b733faf0eb47520e4ff7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745302881,
      "headline": "Bristol-Myers Squibb: Extraordinary Dividend And FCF Yields Ready For Recession",
      "id": 134031203,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=2383ceb3bd63593652dd9ff902c086f52601c8a595b8b733faf0eb47520e4ff7"
    }
  }
]